Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Long-Term Deferred Tax (2016 - 2025)

Adma Biologics' Long-Term Deferred Tax history spans 4 years, with the latest figure at $73.3 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 13.07% year-over-year to $73.3 million; the TTM value through Dec 2025 reached $73.3 million, down 13.07%, while the annual FY2025 figure was $73.3 million, 13.07% down from the prior year.
  • Long-Term Deferred Tax reached $73.3 million in Q4 2025 per ADMA's latest filing, down from $74.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $84.3 million in Q4 2024 to a low of $73.3 million in Q4 2025.